人α2（I）型胶原基因启动子活性研究

目的 探索器官纤维化形成中调控I型胶原基因高水平转录的启动片段及TGF-β、PDGF－BB、IGF－1等细胞因子对其活性的影响。方法 从人α2（I）胶原基因转录起始点上游－2.4kb至＋58bp的片段中，取长度不等的片段作为启动子与含氯霉素乙酰基转移酶（CAT）报告基因的质粒组成5个重组体，转染上述重组体至正常人原代培养皮肤成纤维细胞，测定细胞CAT表达水平以比较各重组体的启动子活性，同时加入细胞因子，以测定其对I型胶原启动序列的影响。结果 除－129～＋58bp序列外，其余4个重组体CAT表达水平均较高，其中－2292～＋58bp、－1476～ 58bp序列具较强启动CAT表达活性，－339～ 58bp、－616～ 58bp片段次之。TGF－β、IGF－1均能在一定程度上调人α2（I）胶原基因启动活性。结论 人α2（I）胶原基因片段－2292～ 58bp、－1476～ 58bp、－339～ 58bp有高启动活性，是进一步研究纤维化相关DNA结合蛋白的重要调控靶序列。TGF－β、IGF－1促进胶原表达，与其上调胶原基因启动活性有关。     

中国东部汉族人群原发性胆汁性肝硬化与HLA-DRB1相关性分析

目的：探讨组织相容性抗原Ⅱ类HLA—DRB1等位基因与原发性肝汁性肝硬化（Primary biliary cirrhosis，PBC）患者人群的相关性。方法：采用序列特异性引物PCR（SSP．PCR）对105例确诊PBC患者，400例健康人群进行HLA-DRB1等位基因及相关亚型基因分析。结果：PBC患者组DRB1＊07的频率为37．26％，与正常人组的13．8％相比存在显著性差异（P〈0．05，比数比为2．7），所有阳性患者经亚型分析均为DRB1＊0701；其余DRB1的等位基因频率与正常对照组比较无显著性差异。DRB1＊0701阳性与阴性患者群体的疾病进程、临床指征、实验室指征等无显著性差异。绪论：中国人群PBC患者可能与DRB1＊0701易感性相关，为临床治疗提供了一定线索。     

类风湿性关节炎大小鼠动物模型的研究进展

类风湿性关节炎(rheumatoid arthritis,RA)是一种常见的自身免疫性疾病,致残率高,其病理机制尚不明确。构建合适的尤其是与人RA发病相似的动物模型在研究RA的发病机制和临床治疗方面具有十分重要的意义。而所构建类风湿性关节炎模型所选择的大小鼠品系和方法很多,各种动物模型都有其各自的侧重点。现针对所报道的RA有关的趋于成熟与稳定的大小鼠动物模型进行综述。     

Who will become my co-residents? The role of attractiveness of institutional care in the changing demand for long-term care institutions

BackgroundIn several OECD countries the percentage of people over 80 in LTC institutions has been declining for more than a decade, despite population ageing. The standard model to explain healthcare utilization, the Andersen model, cannot explain this trend. We extend the Andersen model by including proxies for the relative attractiveness of community living compared to institutional care. Using longitudinal data on long-term care use in the Netherlands from 1996 to 2012, we examine to what extent a decline in institutional care is associated with changes in perceived attractiveness of institutional LTC care compared to community living.MethodsWith a Blinder–Oaxaca decomposition regression, we decomposed the difference in admission to LTC institutions between the period 1996–1999 and 2009–2012 into a part that accounts for differences in predictors of the Andersen model and an “unexplained” part, and investigate whether the perceived attractiveness of institutional care reduces the size of the unexplained part.ResultsWe find that factors related to the perceived attractiveness of institutional care compared to community living explains 12.8% of the unexplained negative time trend in admission rates over the total period (1996–2012), and 19.1–19.2% over shorter time frames.DiscussionOur results show that changes in the perceived attractiveness of institutional LTC may explain part of the decline in demand for institutional care. Our findings imply that policies to encourage community living may have a self-reinforcing effect.     

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis

A recombinant vector vaccine uses an attenuated virus, bacterium, or parasite as the carrier to express a heterologous antigen(s). Many recombinant vaccine vectors and related vaccines have been developed and extensively investigated. To compare and better understand recombinant vectors and vaccines, we have generated Vaxvec (http://www.violinet.org/vaxvec), the first web-based database that stores various recombinant vaccine vectors and those experimentally verified vaccines that use these vectors. Vaxvec has now included 59 vaccine vectors that have been used in 196 recombinant vector vaccines against 66 pathogens and cancers. These vectors are classified to 41 viral vectors, 15 bacterial vectors, 1 parasitic vector, and 1 fungal vector. The most commonly used viral vaccine vectors are double-stranded DNA viruses, including herpesviruses, adenoviruses, and poxviruses. For example, Vaxvec includes 63 poxvirus-based recombinant vaccines for over 20 pathogens and cancers. Vaxvec collects 30 recombinant vector influenza vaccines that use 17 recombinant vectors and were experimentally tested in 7 animal models. In addition, over 60 protective antigens used in recombinant vector vaccines are annotated and analyzed. User-friendly web-interfaces are available for querying various data in Vaxvec. To support data exchange, the information of vaccine vectors, vaccines, and related information is stored in the Vaccine Ontology (VO). Vaxvec is a timely and vital source of vaccine vector database and facilitates efficient vaccine vector research and development.     

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

BackgroundNew, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4:IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B, formulated in IC31^® adjuvant. We assessed the safety and immunogenicity of H4:IC31 in South African adults from a TB endemic setting.MethodsIn this double blind, placebo controlled, phase I trial, Mycobacterium tuberculosis-uninfected, HIV-uninfected, healthy adults with a history of childhood BCG vaccination were randomly allocated to two intramuscular vaccinations with 5, 15, 50 or 150 μg H4 formulated in 500 nmol IC31^®, two months apart. Vaccinees were followed for six months to assess safety; immunogenicity was measured by ELISpot and intracellular cytokine staining assays.ResultsThirty-two participants received H4:IC31 and 8 received placebo. Injection site adverse events were common but mild; mild fatigue was the most common systemic adverse event. Frequencies of adverse events did not differ between dosage groups. Detectable antigen-specific CD4 T cell responses were induced by all doses of H4:IC31, but doses below 50 μg induced the highest frequencies of CD4 T cells, comprised predominantly of IFN-γ⁺TNF-α⁺IL-2⁺ or TNF-α⁺IL-2⁺ cells. These memory responses persisted up to the end of follow up, on study day 182.ConclusionsH4:IC31 demonstrated an acceptable safety profile and was immunogenic in South African adults. In this trial, the 15 μg dose appeared to induce the most optimal immune response.